Plain-English translation of NCT07008287 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of a medication called for people with advanced lung cancer that has spread to the brain. Researchers are observing how well this treatment works and how safe it is when used in everyday medical practice, rather than in a controlled trial setting. If you're already taking this medication or are about to start it, doctors may invite you to participate by sharing your treatment outcomes and health information.
While earlier studies showed promise for this medication in the lab and in controlled settings, doctors need to understand how well it actually works and how safe it is for real patients with brain metastases in everyday clinical practice. This study helps bridge that gap by collecting real-world evidence.
You likely qualify if…
You likely don't qualify if…
If you join, you won't need to do anything new — you'll continue taking your medication as prescribed by your regular doctor. Researchers will collect information about your treatment and health during your routine clinic visits and scans, tracking how well the medication is working, any side effects you experience, and how long you respond to treatment. The study involves about 100 patients across multiple hospitals and continues as long as your doctor believes the treatment is helping you.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China
Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Enrollment target
~100 participants
Started
June 2025
Primary completion
June 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.